TEMODEX - SI 05328 Dec 2022 17:41
John
You don't speak or read Scandinavian, so here comes an announcement from DBP Stockholm that owns 75% of Temodex or as the real name is SI 053, Temodex is the Russian version that is in use today
https://www.placera.se/placera/telegram/2022/11/16/dbp-500-meur-for-si-053-med-mycket-konservativa-antaganden-vd.html
Under Google translate
DBP
500 MEUR FOR SI-053 WITH VERY CONSERVATIVE ASSUMPTIONS - CEO (Direct)
2022-11-16 12:29
STOCKHOLM (Direkt Studios) Double Bond Pharmaceutical is on the radar of key opinion leaders globally and is in discussions with potential partners regarding
the brain tumor drug SI-053.
This was announced by CEO Igor Lokot at Wednesday's Mangold Insight Investor Day.
He explained that with very conservative assumptions, SI-053 could generate 500 million euros in gross revenue. It is based on the drug taking 10 percent of the seven largest glioblastoma markets.
The company's great hope is that within four to six years SI-053 will be part of the standard treatment against brain tumors, according to Igor Lokot.
The CEO explained that the number of promising projects in the area has decreased in recent years, based on conversations the company has had with experienced doctors. Therefore, the focus is big on SI-053 and it is important that Double Bond Pharmaceutical fine-tune the protocol and make the candidate as attractive as possible in order not to jeopardize future clinical trials, it was stated.
"That's why we choose the best clinics in Europe with well-known key opinion leaders and with very well-known principal investigators for upcoming clinical trials," said Igor Lokot.
The presentation is broadcast live on Direkt Studio's YouTube channel:
https://www.youtube.com/watch?v=dQe8KRxaFWg
The event is filmed on behalf of Mangold Insight. Direkt Studios is responsible for technical production and distribution, Mangold Insight and the respective companies presented are responsible for the content. Direkt Studios is an independent operation within Nyhetsbyrån Direkt, and the production is entirely disconnected from Nyhetsbyrån Direkt's other editorial staff.
Direct Studios +46 8 5191 7900
News agency Direkt
Sign In
Follow the stocks
